- Home
- BCRX vs KYMR Comparison
BCRX vs KYMR Comparison
Compare BCRX & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- KYMR
- Stock Information
- Founded
- BCRX 1986
- KYMR 2015
- Country
- BCRX United States
- KYMR United States
- Employees
- BCRX N/A
- KYMR N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- BCRX Health Care
- KYMR Health Care
- Exchange
- BCRX Nasdaq
- KYMR Nasdaq
- Market Cap
- BCRX 1.7B
- KYMR 1.8B
- IPO Year
- BCRX 1994
- KYMR 2020
- Fundamental
- Price
- BCRX $10.09
- KYMR $45.87
- Analyst Decision
- BCRX Buy
- KYMR Strong Buy
- Analyst Count
- BCRX 8
- KYMR 16
- Target Price
- BCRX $16.75
- KYMR $59.38
- AVG Volume (30 Days)
- BCRX 3.5M
- KYMR 1.1M
- Earning Date
- BCRX 08-04-2025
- KYMR 08-06-2025
- Dividend Yield
- BCRX N/A
- KYMR N/A
- EPS Growth
- BCRX N/A
- KYMR N/A
- EPS
- BCRX N/A
- KYMR N/A
- Revenue
- BCRX $503,485,000.00
- KYMR $58,885,000.00
- Revenue This Year
- BCRX $39.04
- KYMR $43.38
- Revenue Next Year
- BCRX $13.26
- KYMR $10.97
- P/E Ratio
- BCRX N/A
- KYMR N/A
- Revenue Growth
- BCRX 41.67
- KYMR N/A
- 52 Week Low
- BCRX $5.92
- KYMR $19.45
- 52 Week High
- BCRX $11.31
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- BCRX 43.54
- KYMR 67.58
- Support Level
- BCRX $9.84
- KYMR $45.80
- Resistance Level
- BCRX $10.47
- KYMR $47.51
- Average True Range (ATR)
- BCRX 0.34
- KYMR 2.86
- MACD
- BCRX -0.19
- KYMR -0.03
- Stochastic Oscillator
- BCRX 8.16
- KYMR 67.19
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.